相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists
Sten Madsbad
DIABETES OBESITY & METABOLISM (2016)
Lowering blood pressure in diabetes
Seema Kang
LANCET DIABETES & ENDOCRINOLOGY (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people
Anoop Dinesh Shah et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
Blood Pressure Lowering in Type 2 Diabetes A Systematic Review and Meta-analysis
Connor A. Emdin et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
David Z. I. Cherney et al.
CIRCULATION (2014)
Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored
John J. V. McMurray et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial
Steven P. Marso et al.
AMERICAN HEART JOURNAL (2013)
Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-A randomized placebo-controlled trial
Bruce Neal et al.
AMERICAN HEART JOURNAL (2013)
Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials
B. Wang et al.
DIABETES OBESITY & METABOLISM (2013)
Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus
William N. Washburn et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM)
Jan N. Basile
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial
William T. Abraham et al.
LANCET (2011)
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
N. Sarwar et al.
LANCET (2010)
Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials
Kausik K. Ray et al.
LANCET (2009)
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Rosiglitazone evaluated for cardiovascular outcomes - An interim analysis
Philip D. Home et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)